77V Stock Overview
An investment holding company, engages in the in-house discovery and development of oncology therapies. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Jacobio Pharmaceuticals Group Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.17 |
| 52 Week High | HK$0.27 |
| 52 Week Low | HK$0.15 |
| Beta | 0.59 |
| 1 Month Change | 9.15% |
| 3 Month Change | -18.93% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -7.58% |
Recent News & Updates
Recent updates
Shareholder Returns
| 77V | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 2.5% | 1.0% | 2.0% |
| 1Y | n/a | -4.8% | 15.2% |
Return vs Industry: Insufficient data to determine how 77V performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how 77V performed against the German Market.
Price Volatility
| 77V volatility | |
|---|---|
| 77V Average Weekly Movement | 6.0% |
| Biotechs Industry Average Movement | 6.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 77V has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 77V's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 298 | Yinxiang Wang | www.jacobiopharma.com |
Jacobio Pharmaceuticals Group Co., Ltd., an investment holding company, engages in the in-house discovery and development of oncology therapies. The company’s drug development programs include Glecirasib (JAB-21822), a KRAS G12C inhibitor currently under multiple stage studies for indications, including NSCLC, PDAC, CRC and other solid tumors; JAB-3068, an SHP2 inhibitor approved by the FDA to enter clinical development for the treatment of esophageal cancer, including esophageal squamous cell carcinoma; and JAB-3312, an SHP2 inhibitor with multiple indications, such as KRAS G12C mut NSCLC under Phase III pivotal study, and Osimertinib progressed NSCLC under Phase I study, as well as NSCLC, HNSCC, and ESCC under Phase IIa studies. It also develops JAB-23E73 currently under IND-enabling studies for targeting multiple KRAS mutants indicated for PDAC, CRC, and NSCLC; JAB-BX300, a self-developed LIF mAb, under IND study indicated for the treatment of solid tumors; JAB-22000, a small-molecule KRAS G12D inhibitor, under lead optimization study indicated for PDAC, CRC, and NSCLC treatments; and JAB-8263, a Bromodomain and Extra-Terminal motif (BET) inhibitor, under Phase I studies indicated for MF, AML, and solid tumor.
Jacobio Pharmaceuticals Group Co., Ltd. Fundamentals Summary
| 77V fundamental statistics | |
|---|---|
| Market cap | €138.68m |
| Earnings (TTM) | -€48.15m |
| Revenue (TTM) | €3.08m |
45.0x
P/S Ratio-2.9x
P/E RatioIs 77V overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 77V income statement (TTM) | |
|---|---|
| Revenue | CN¥23.19m |
| Cost of Revenue | CN¥22.38m |
| Gross Profit | CN¥801.00k |
| Other Expenses | CN¥362.69m |
| Earnings | -CN¥361.89m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.46 |
| Gross Margin | 3.45% |
| Net Profit Margin | -1,560.88% |
| Debt/Equity Ratio | 7.0% |
How did 77V perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/31 00:50 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Jacobio Pharmaceuticals Group Co., Ltd. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ziyi Chen | Goldman Sachs |